Use of half the iodinated contrast medium for monitoring thoracic neoplasms using spectral CT: Randomized, crossover, non-inferiority clinical trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524901-33-00

Enrollment

Registered

2026-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic neoplasm

Brief summary

Vascular attenuation and signal-to-noise ratio., Hepatic attenuation and signal-to-noise ratio., Subjective assessment of overall image quality and image noise.

Detailed description

To analyze the agreement between two readers in the assessment of the evaluated parameters.

Interventions

DRUGIomeron 400 mgI/ml solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Vascular attenuation and signal-to-noise ratio., Hepatic attenuation and signal-to-noise ratio., Subjective assessment of overall image quality and image noise.	—

Secondary

Measure	Time frame
To analyze the agreement between two readers in the assessment of the evaluated parameters.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 18, 2026